PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis
by: M. Untch, G. von Minckwitz, G. E. Konecny, U. Conrad, W. Fett, C. Kurzeder, H. J. Lück, E. Stickeler, H. Urbaczyk, B. Liedtke, M. W. Beckmann, C. Salat, N. Harbeck, V. Müller, M. Schmidt, S. Hasmüller, M. Lenhard, V. Nekljudova, A. Lebeau, S. Loibl, P. A. Fasching, on behalf of the Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators
Annals of Oncology, Vol. 22, No. 9. (01 September 2011), pp. 1999-2006, doi:10.1093/annonc/mdq713 Key: citeulike:9761845
Formatted Citation
Show HTML
Likes (beta)
This copy of the article hasn't been liked by anyone yet.
View FullText article
Abstract
Background: The objective of this study was to compare the effect of dose-intensified neoadjuvant chemotherapy with that of standard epirubicin plus cyclophosphamide followed by paclitaxel in combination with or without darbepoetin on survival in primary breast cancer.
eraderna's tags for this article
Citations (CiTO)
No CiTO relationships defined
There are no reviews yet
